Please login to the form below

Not currently logged in
Email:
Password:

MYSTIC trial

This page shows the latest MYSTIC trial news and features for those working in and with pharma, biotech and healthcare.

AZ to address Imfinzi setback, but sees potential with Tagrisso

AZ to address Imfinzi setback, but sees potential with Tagrisso

During the MYSTIC trial, Imfinzi failed to hit the mark on progression-free survival and overall survival endpoints, but AstraZeneca said it would try the drug’s luck as a monotherapy ... However, AZ has confirmed that Imfinzi did demonstrate clinical

Latest news

  • AZ still sees route to approval for Imfinzi in MYSTIC trial AZ still sees route to approval for Imfinzi in MYSTIC trial

    expand and tweak the protocol of its ongoing NEPTUNE trial of Imfinzi with tremelimumab in first-line NSCLC that is due to generate results early next year. ... month and it is hard to explain why the duo performed worse than Imfinzi on its own in MYSTIC.

  • Is AstraZeneca looking for its next CEO? Is AstraZeneca looking for its next CEO?

    The rumour has surfaced just days after the company confirmed that its immuno-oncology (IO) combination trial MYSTIC (twinning Imfinzi with CTLA4 candidate tremelimumab) failed to outperform chemo in overall survival

  • AZ’s MYSTIC survival data is in – and it’s a bust AZ’s MYSTIC survival data is in – and it’s a bust

    Imfinzi failed to achieve OS improvement. AstraZeneca has released the overall survival (OS) data from its MYSTIC trial of Imfinzi and tremelimumab in advanced non-small cell lung cancer (NSCLC), and

  • AZ swells immuno-oncology pipeline with Innate deal AZ swells immuno-oncology pipeline with Innate deal

    two primary endpoints in the MYSTIC trial of Imfinzi plus AZ’s experimental CTLA4 inhibitor tremelimumab in first-line lung cancer treatment.

  • Imfinzi aces survival challenge in lung cancer Imfinzi aces survival challenge in lung cancer

    PD-L1 inhibitor Imfinzi (durvalumab) reduced the risk of death by 32% compared to placebo after standard chemotherapy in the PACIFIC trial, consolidating earlier results which showed that the drug extended ... The new data is a big boost to AZ’s

More from news
Approximately 1 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    The NELSON trial, which looked at screening in Europe, was presented at the recent World Conference on Lung Cancer. ... However, recent overall survival results from the MYSTIC trial, which studied Imfinzi with CTLA4 inhibitor tremelimumab, have just

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    Open-minded culture. Like the new HQ’s construction, there have been setbacks – such as the setback to its Imfinzi tremelimumab immunotherapy combination in the MYSTIC lung cancer trial last year –

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics